Search hospitals > Pennsylvania > Philadelphia

Children's Hospital of Philadelphia

Claim this profile
Philadelphia, Pennsylvania 19104
Global Leader in Brain Tumor
Global Leader in Cancer
Conducts research for Neuroblastoma
Conducts research for Solid Tumors
Conducts research for Acute Lymphoblastic Leukemia
1798 reported clinical trials
169 medical researchers
Photo of Children's Hospital of Philadelphia in PhiladelphiaPhoto of Children's Hospital of Philadelphia in PhiladelphiaPhoto of Children's Hospital of Philadelphia in Philadelphia

Summary

Children's Hospital of Philadelphia is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Brain Tumor, Cancer, Neuroblastoma, Solid Tumors, Acute Lymphoblastic Leukemia and other specialties. Children's Hospital of Philadelphia is involved with conducting 1,798 clinical trials across 1,932 conditions. There are 169 research doctors associated with this hospital, such as Theodore W. Laetsch, Frank M Balis, Michael J Fisher, MD, and Nancy J Bunin, MD.

Area of expertise

1Brain Tumor
Global Leader
Children's Hospital of Philadelphia has run 142 trials for Brain Tumor. Some of their research focus areas include:
Stage IV
NTRK positive
Stage II
2Cancer
Global Leader
Children's Hospital of Philadelphia has run 128 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage I
Stage II

Top PIs

Clinical Trials running at Children's Hospital of Philadelphia

Crohn's Disease
Chronic Kidney Disease
Testicular cancer
Polycystic Kidney Disease
Neuroblastoma
Sickle Cell Disease
Inflammatory Bowel Disease
Spinal Muscular Atrophy
Ovarian Carcinoma
Ovarian Tumors
Image of trial facility.

Anti-TNF Therapy

for Crohn's Disease in Children

Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause of CD is not certain it is thought that the immune system located in the intestine reacts abnormally to the large number of bacteria contained there. The investigators think that diet, exposure to antibiotics early in life, and having a family history of CD puts people at increased risk for developing CD. In order to decrease the inflammation doctors use what is called biologic therapy with anti-TNF molecules that can be given through an intravenous or shots. TNF is a chemical made by white blood cells that is involved in inflammation. When this type of treatment is given early after diagnosis it is more effective than when it is given later. The investigators have learned that it is important to give the optimum (ideal) amount of this medicine guided by certain blood tests. The investigators also know that not everyone responds to this therapy but do not understand the reasons for this variability between people. The CAMEO study has been started to help understand what factors are important in determining whether a child with CD completely heals the inflammation after anti-TNF therapy. The investigators will do that by measuring certain markers of inflammation in the blood and stool and by looking at a person's genes (DNA) and how inflammation is controlled in the intestine. These inflammation tests will be done before, during, and after one year of anti-TNF therapy. The investigators will determine how much healing has taken place by comparing the results of the colonoscopy and a special type of MRI that are both done before anti-TNF and then again one year later. The goal in treating CD is to heal both the lining and the wall of the intestine. Children ages 6-17 years who are thought to have CD and are about to undergo their diagnostic colonoscopy are eligible to be enrolled. If they are found to indeed have CD and start an anti-TNF medicine within 6 months they can continue in the study. There are no increased risks of participating in this study beyond those normally associated with having CD and its treatment. By better understanding why the bowel does or does not heal, doctors will be better able to provide personalized care.
Recruiting3 awards Phase 47 criteria
Image of trial facility.

Mirikizumab

for Pediatric Crohn's Disease

Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease. Study periods for the intervention-specific appendix (ISA) will be as follows: * A 12-week induction period * A maintenance period from Week 12 to Week 52, and * A safety follow-up period up to 16 weeks. The study will last about 74 weeks and may include up to 19 visits.
Recruiting2 awards Phase 3
Image of trial facility.

Guselkumab

for Pediatric Crohn's Disease

This trial tests guselkumab, an anti-inflammatory medication, on children with Crohn's Disease who initially responded well to it. The goal is to see if the benefits last over several months by reducing immune system activity. Guselkumab has shown effectiveness in treating moderate-to-severe psoriasis and psoriatic arthritis.
Recruiting2 awards Phase 3

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Children's Hospital of Philadelphia?
Where is Children's Hospital of Philadelphia located?
Who should I call to ask about financial aid or insurance network?
What insurance does Children's Hospital of Philadelphia accept?
What awards or recognition has Children's Hospital of Philadelphia received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security